Novanta (NOVT) Projected to Post Earnings on Tuesday

Novanta (NASDAQ:NOVT) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.88 per share and revenue of $260.7220 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Novanta Stock Performance

Novanta stock opened at $145.96 on Monday. The company has a 50 day moving average price of $131.69 and a 200-day moving average price of $119.68. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.54 and a current ratio of 2.51. Novanta has a fifty-two week low of $98.27 and a fifty-two week high of $153.20. The company has a market capitalization of $5.22 billion, a PE ratio of 99.29 and a beta of 1.62.

Insider Buying and Selling at Novanta

In other Novanta news, CFO Robert Buckley sold 1,423 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $140.14, for a total transaction of $199,419.22. Following the sale, the chief financial officer owned 91,034 shares of the company’s stock, valued at approximately $12,757,504.76. This trade represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthijs Glastra sold 7,500 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $145.04, for a total value of $1,087,800.00. Following the completion of the transaction, the chief executive officer directly owned 57,367 shares of the company’s stock, valued at approximately $8,320,509.68. The trade was a 11.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 22,923 shares of company stock worth $3,182,264 in the last ninety days. Insiders own 1.20% of the company’s stock.

Institutional Trading of Novanta

Institutional investors have recently modified their holdings of the company. Invesco Ltd. raised its stake in shares of Novanta by 9.0% during the 4th quarter. Invesco Ltd. now owns 68,089 shares of the technology company’s stock worth $8,102,000 after acquiring an additional 5,600 shares in the last quarter. Corient Private Wealth LLC purchased a new position in Novanta in the fourth quarter worth $275,000. Alberta Investment Management Corp acquired a new position in shares of Novanta during the fourth quarter worth $1,285,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Novanta during the 4th quarter valued at $314,000. Finally, Empowered Funds LLC lifted its holdings in shares of Novanta by 16.7% during the 4th quarter. Empowered Funds LLC now owns 7,888 shares of the technology company’s stock valued at $939,000 after purchasing an additional 1,128 shares during the last quarter. 98.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on NOVT shares. Zacks Research upgraded Novanta from a “strong sell” rating to a “hold” rating in a report on Friday, January 16th. Weiss Ratings upgraded Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 20th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, Novanta currently has a consensus rating of “Hold” and an average target price of $133.00.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.